NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST's HVP business and GLP-1 demand are driving growth, but can Annex 1 tailwinds and margin gains offset inflation and SmartDose risks?
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.